Monotherapy for Rheumatoid Arthritis: Leveraging the Latest Evidence to Treat to Target

In this CME/CNE/CPE-certified video module with accompanying downloadable slides and expert-authored ClinicalThought commentaries, learn best practices in the use of traditional, biologic, and targeted synthetic DMARD monotherapy to treat rheumatoid arthritis and discover new strategies for the multidisciplinary engagement of patients with this condition.
Jonathan Scott Coblyn, MD
Program Director
Jessica Farrell, PharmD
Roy Fleischmann, MD
Frances Griffin, RN, BSN

ClinicalThought

Here’s my take on the patients who are best suited to receive biologic or targeted synthetic DMARD monotherapy.

Roy Fleischmann, MD Released: June 8, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Pfizer Inc.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?